Advertisement

Topics

Japan Grants Marketing Approval to Lilly Rheumatoid Arthritis Drug

06:25 EDT 5 Jul 2017 | PharmPro

Japan Ministry of Health, Labor and Welfare (MHLW) grants marketing approval for Olumiant (baricitinib) for the treatment of rheumatoid arthritis. The marketing authorization triggers a $15 million milestone payment from Lilly to Incyte Corporation.
Contributed Author: 
Eli Lilly and Company
Topics: 

Original Article: Japan Grants Marketing Approval to Lilly Rheumatoid Arthritis Drug

NEXT ARTICLE

More From BioPortfolio on "Japan Grants Marketing Approval to Lilly Rheumatoid Arthritis Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...

Lilly
Eli Lilly and Company was founded in 1876, and is now the 9th largest pharmaceutical company based an annual sales which were just under $20bn in 2009. Orginally from the USA, Lilly now operates in over 50 countries with just under 40,000 employees. Appr...